| Literature DB >> 27846768 |
Imen Ghorbel1, Awatef Elwej1, Nesrine Fendri2, Héla Mnif3, Kamel Jamoussi2, Tahia Boudawara3, Naziha Grati Kamoun4, Najiba Zeghal1.
Abstract
Acrylamide (ACR) is one of the most important contaminants occurring in foods heated at high temperatures. The aim of this study is to investigate the protective efficacy of extra virgin olive oil (EVOO), a main component of the Mediterranean diet, against nephrotoxicity induced by ACR. Rats have received by gavage during 21 days either ACR (40 mg/kg body weight) or ACR-associated with EVOO (300 μl) or only EVOO (300 μl). Acrylamide induced nephrotoxicity as evidenced by an increase in malondialdehyde (MDA), hydrogen peroxide (H2O2), protein carbonyls (PCOs) and a decrease in glutathione, non-protein thiols (NPSHs), and vitamin C levels. Activities of catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx) were also decreased. Lactate dehydrogenase (LDH) activity, creatinine, urea, and uric acid, urinary volume and creatinine clearance levels were modified. EVOO supplementation improved all the parameters indicated above. Kidney histoarchitecture confirmed the biochemical parameters and the beneficial role of EVOO. EVOO, when added to the diet, may have a beneficial role against kidney injury by scavenging free radicals and by its potent antioxidant power.Entities:
Keywords: Acrylamide; antioxidant status; extra virgin olive oil; nephrotoxicity; rats
Mesh:
Substances:
Year: 2016 PMID: 27846768 PMCID: PMC6014333 DOI: 10.1080/0886022X.2016.1256320
Source DB: PubMed Journal: Ren Fail ISSN: 0886-022X Impact factor: 2.606
Analytical parameters of EVOO.
| Analytical parameters | Mean values |
|---|---|
| Free acidity (g/100 g) | 0.41 |
| K232 | 2 |
| K270 | 0.16 |
| PV (meqO2/kg) | 7.5 |
| Palmitic acid (C16:0) | 12.68 ± 0.12 |
| Palmitoleic acid (C16:1w7) | 0.54 ± 0.04 |
| Stearic acid (C18:0) | 2.80 ± 0.06 |
| Oleic acid (C18:1w9) | 66.35 ± 0.39 |
| Linoleic acid (C18:2w6) | 16.03 ± 0.41 |
| Linolenic acid (C18:3w3) | 0.70 ± 0.03 |
| Arachidonic acid (C20:0) | 0.44 ± 0.02 |
| Gadoleic acid (C20:1w-9) | 0.34 ± 0.10 |
| SFA | 15.98 ± 0.13 |
| MUFA | 67.23 ± 0.37 |
| PUFA | 16.73 ± 0.43 |
| MUFA/PUFA | 4.02 ± 0.13 |
| Chlorophylls | 7.40 ± 0.06 |
| β-Carotene | 9.17 ± 0.51 |
| Total polyphenols | 486.01 ± 62.26 |
| α-tocopherol | 1242.66 ± 75.26 |
| β-tocopherol | 46.26 ± 10.01 |
MUFA: monounsaturated fatty acid; PUFA: polyunsaturated fatty acid; SFA: saturated fatty acids.
Initial and final body weights, absolute kidney weight, daily food and water consumption in control and treated rats with ACR, EVOO and their combination (ACR + EVOO) during 21 days.
| Parameters and treatment | Controls | ACR | ACR + EVOO | EVOO |
|---|---|---|---|---|
| Initial body weights (g) | 161 ± 2.88 | 162.31 ± 1.49 | 162.69 ± 1. 19 | 161.5 ± 3.81 |
| Final body weight (g) | 180.33 ± 6.81 | 167.72 ± 1.96 *** | 182. 5 ± 2.97+++ | 185.51 ± 5.32 |
| Absolute kidney weights (g) | 1.22 ± 0.11 | 0.97 ± 0.07 *** | 1.18 ± 0.03++ | 1.27 ± 0.03 |
| Food consumption (g/day/rat) | 12.39 ± 2.23 | 9.86 ± 1.44 *** | 12.51 ± 1.11+++ | 11.75 ± 0.89 |
| Drinking water intake (ml/day/rat) | 27.92 ± 4.32 | 22.81 ± 2.13 *** | 25.96 ± 1.64 * +++ | 26.17 ± 2.03 |
Values are means ± SE for six rats in each group.
ACR; (ACR + EVOO) and EVOO treated groups vs. control group: *p < .05; ***p < .001.
(ACR + EVOO) group vs. ACR group: ++p < .01; +++p < .001.
MDA, HO, PCO, GSH, NPSH and vitamin C levels in the kidney of control and treated rats with ACR, EVOO and their combination during 21 days of treatment.
| Parameters & treatment | Controls | ACR | ACR + EVOO | EVOO |
| MDA | 2.03 ± 0.43 | 5.85 ± 0.75*** | 2.96 ± 0.34+++* | 2.61 ± 0.36 |
| H2O2 | 29.03 ± 2.45 | 47.34 ± 2.97*** | 26.61 ± 2.51+++ | 30.92 ± 1.94 |
| PCO | 1.56 ± 0.22 | 3.25 ± 0.34*** | 1.76 ± 0.19+++ | 1.45 ± 0.08 |
| GSH | 9.71 ± 0.52 | 6.25 ± 0.75*** | 9.35 ± 0.92+++ | 9.46 ± 0.76 |
| NPSH | 31.65 ± 3.03 | 22.99 ± 3.15*** | 29.42 ± 2.47++ | 29.96 ± 2.24 |
| Vitamin C | 1.51 ± 0.13 | 0.83 ± 0.17*** | 1.41 ± 0.13+++ | 1.46 ± 0.19 |
nmoles of MDA/mg protein.
nmoles/mg protein.
μg/mg protein.
μmol/mg protein.
Values are means ± SE for six rats in each group.
ACR; (ACR + EVOO) and EVOO treated groups vs. control group: *p < .05; ***p < .001.
(ACR + EVOO) group vs. (ACR) group: ++ p < .01; +++p < .001.
Figure 1.Antioxidant enzyme activities (CAT, GPx and SOD) in the kidney of control and treated rats with ACR, EVOO and their combination (ACR + EVOO) during 21 days. Values are means ± SE for six rats in each group. ACR, (ACR + EVOO) and EVOO treated groups vs. control group: ***p < .001. (ACR + EVOO) group vs. ACR group: +++p < .001.
Figure 2.LDH activities in plasma and in kidney of control and treated rats with ACR, EVOO and their combination (ACR + EVOO) during 21 days. Values are means ± SE for six rats in each group. ACR, (ACR + EVOO) and EVOO treated groups vs. control group: ***p < .001. (ACR + EVOO) group vs. ACR group: +++p < .001.
Plasma and urinary levels of creatinine, urea and uric acid and creatinine clearance of control and treated rats with ACR, (EVOO) and their combination (ACR + EVOO) during 21 days.
| Parameters and treatments | Control | ACR | ACR + EVOO | EVOO |
|---|---|---|---|---|
| Plasma | 129.58 ± 4.77 | 170.15 ± 6.02*** | 130.33 ± 6.53+++ | 132.69 ± 3.37 |
| Urine | 4612 ± 423.58 | 2586 ± 261.41*** | 4530 ± 367.85+++ | 4565.5 ± 211.42 |
| Plasma | 4.73 ± 0.39 | 7.2 ± 0.46*** | 5.53 ± 0.32+++* | 4.81 ± 0.23 |
| Urine | 439.36 ± 44.99 | 146.8 ± 13.72*** | 423.2 ± 30.63+++ | 427.4 ± 20.57 |
| Plasma | 255.67 ± 3.95 | 229.72 ± 4.47*** | 248.11 ± 5.39* +++ | 252.71 ± 4.11 |
| Urine | 1420 ± 277.49 | 1969 ± 165.62** | 1474.8 ± 87.21+++ | 1488 ± 80.75 |
| Urinary volume | 9.68 ± 0.81 | 11.4 ± 0.71** | 10.02 ± 0.53++ | 10.16 ± 0.59 |
| Creatinine clearance | 357.51 ± 26.52 | 174.09 ± 17.15*** | 374.01 ± 17.09+++ | 366.54 ± 25.26 |
Values were expressed as means ± SD. The number of determinations was n = 6.
ACR, (ACR + EVOO) and EVOO groups vs. control group: *p < .05; **p < .01; ***p < .001.
(ACR + EVOO) vs. ACR: ++p < .01; +++p < .001.
Figure 3.Histological kidney sections of control (A) and treated rats with ACR (B1, B2 and B3), EVOO and ACR (C) and EVOO (D) during 21 days. Arrows indicate: glomeruli showing enlarged Bowman’s space, tubular dilatation, infiltration of leucocyte cells, hemorrhage glomeruli fragmentation